Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 14/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.73 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.72 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.64 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148675 | 1.00 | P2RY6 (0.73) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL9702628 | 0.98 | P2RY6 (0.74) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL9702618 | 0.98 | P2RY6 (0.74) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL8861497 | 0.94 | P2RY6 (0.75) | P2RY6P2RY2P2RY14NT5E | |
| SCHEMBL6820202 | 0.92 | P2RY6 (0.63) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL16081117 | 0.92 | P2RY2 (0.72) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL6820199 | 0.92 | P2RY6 (0.63) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL28741430 | 0.90 | P2RY6 (0.74) | P2RY6P2RY2P2RY14NT5EDNPH1 | |
| SCHEMBL465109 | 0.90 | P2RY6 (0.80) | P2RY6P2RY2P2RY14NT5EDNPH1 | |
| SCHEMBL27686864 | 0.90 | P2RY6 (0.80) | P2RY6P2RY2P2RY14NT5EDNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275562-A1 | CANCER TREATMENT METHODS | STACEY DENNIS W (US) | 2021-09-09 | — | — | US | claimed |
| EP-2935331-B1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2935331-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | AbbVie Inc. (US) | 2015-10-28 | — | — | EP | claimed |
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-14 | — | — | US | claimed |
| WO-2014105810-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC. (US) | 2014-07-03 | — | — | WO | claimed |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-12419893-B2 | Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine | TOSK, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250186435-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATIONS FOR TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2025-06-12 | — | — | US | disclosed |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250121087-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | INTOCELL, INC. (KR) | 2025-04-17 | — | — | US | disclosed |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | INTOCELL, INC. (KR) | 2024-12-17 | — | — | US | disclosed |
| US-5654286-A | Nucleotides for topical treatment of psoriasis, and methods for using same | HOSTETLER KARL Y (US) | 1997-08-05 | — | — | US | disclosed |
| US-5620676-A | ADENOSINE TRIPHOSPHATE DERIVATIVES; TREATMENT OF SEPTIC SHOCK OR BRAIN SEIZURES, LEARNING ENHANCEMENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040166-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0591462-A1 | UNIVERSAL DONOR CELLS | Oklahoma Medical Research Foundation (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1994000560-A1 | MATRIX FOR UNIVERSAL DONOR MICROVASCULAR ENDOTHELIAL CELLS | ALEXION PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1993002188-A1 | UNIVERSAL DONOR CELLS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1993-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227294-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | PRLHR, LHCGR, FCGR2A | P2RY6 2607/4885P2RY2 2361/4885P2RY14 2273/4885 |
| US-20250121087-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | CD274, CD44, H1-3 | P2RY6 3161/4885P2RY2 3679/4885P2RY14 3560/4885 |
| US-12419893-B2 | Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine | UMPS, UNG, UGDH | P2RY6 686/4885P2RY2 872/4885P2RY14 1778/4885 |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | FCGR2A, FCGR3B, FCGR1A | P2RY6 3005/4885P2RY2 2547/4885P2RY14 3131/4885 |
| US-12168060-B2 | Antibody-drug conjugates comprising anti-B7-H3 antibodies | CD274, CD44, H1-3 | P2RY6 3161/4885P2RY2 3679/4885P2RY14 3560/4885 |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | P2RY6 823/4885P2RY2 1008/4885P2RY14 547/4885 |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | P2RY6 3359/4885P2RY2 3988/4885P2RY14 3786/4885 |
| US-20250186435-A1 | PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATIONS FOR TREATMENT OF CANCER | SLC5A1, DPYD, SLC46A1 | P2RY6 281/4885P2RY2 1359/4885P2RY14 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.